<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04811365</url>
  </required_header>
  <id_info>
    <org_study_id>BLU-SM-1101</org_study_id>
    <nct_id>NCT04811365</nct_id>
  </id_info>
  <brief_title>(PROSPECTOR) Screening Study Evaluating the Prevalence of the KIT D816V Mutation in Patients With Systemic Mast Cell Activation</brief_title>
  <official_title>Study Evaluating the Prevalence of the KIT D816V Mutation in Peripheral Blood of Patients With Evidence of Systemic Mast Cell Activation (MCA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Blueprint Medicines Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Blueprint Medicines Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center screening study with the primary objective to determine the prevalence&#xD;
      of KIT D816V mutation in peripheral blood in patients with evidence of systemic mast cell&#xD;
      activation (MCA).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 29, 2021</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with KIT D816V mutation in peripheral blood</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean KIT D816V mutated allele fraction in peripheral blood</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with increased tryptase Alpha/ Beta 1 (TPSAB1) alpha-tryptase gene copy number (GCN) in buccal mucosa</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Systemic Mast Cell Activation</condition>
  <condition>KIT D816V Mutation</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Screening</intervention_name>
    <description>After providing informed consent, relevant medical history data, and blood and buccal swab samples will be collected at a single visit from patients presenting with systemic mast cell activation symptoms</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with systemic mast cell activation&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Presenting with at least one of the three criteria below as evidence of systemic mast&#xD;
             cell activation:&#xD;
&#xD;
               1. Involvement of 2 or more organ systems, characterized by skin (pruritus,&#xD;
                  urticaria, flushing and angioedema), cardiovascular (tachycardia, syncope, and&#xD;
                  hypotension), gastrointestinal (diarrhea, nausea, vomiting, and gastrointestinal&#xD;
                  cramping) or respiratory/naso-ocular (wheezing, conjunctival injection, and nasal&#xD;
                  stuffiness) AND serum basal tryptase levels ≥8 ng/ml. One of the organ systems&#xD;
                  must be the cardiovascular system.&#xD;
&#xD;
               2. Severe, recurrent anaphylaxis (Ring and Messmer grading ≥II) due to Hymenoptera&#xD;
                  sting, regardless of serum basal tryptase levels.&#xD;
&#xD;
               3. Severe, recurrent anaphylaxis (Ring and Messmer grading ≥II), with cardiovascular&#xD;
                  involvement and documented event-related tryptase elevation fitting the formula&#xD;
                  20% of baseline plus 2 ng/ml evaluated in at least 1 event.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient previously diagnosed with any of the following WHO systemic mastocytosis (SM)&#xD;
             sub-classifications: cutaneous mastocytosis only, indolent SM, smoldering SM, SM with&#xD;
             associated hematological neoplasm, aggressive SM, mast cell leukemia, mast cell&#xD;
             sarcoma&#xD;
&#xD;
          -  Patient diagnosed with other myelo- or lympho-proliferative diseases, e.g.,&#xD;
             myelodysplastic syndrome, myeloproliferative neoplasm, etc.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Blueprint Medicines</last_name>
    <phone>1-888-258-7768</phone>
    <email>medinfo@blueprintmedicines.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bernstein Clinical Research Center, LLC</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 10, 2021</study_first_submitted>
  <study_first_submitted_qc>March 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2021</study_first_posted>
  <last_update_submitted>July 20, 2021</last_update_submitted>
  <last_update_submitted_qc>July 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

